FDA Authorization for the Next Generation Sequencer Essay

FDA Authorization for the Next Generation Sequencer - Essay typeIt is apparent that different people respond differently to different drugs, and the use of genome sequencing impart not only reveal the nature and susceptibility of illnesses, but it will also provide physicians with the specific prescriptions take (Collins & Hamburg, 2013). This technology could be used to develop the most appropriate treatment combinations for different patients suffering from cancer. With genomic sequencing, it is possible for doctors to cite the nature of cancer and predict its spreading patterns hence, the new system will be instrumental in helping doctors deal with different forms of cancer more appropriately (Collins & Hamburg, 2013). The authorization of marketing for the genomic sequencer is a step closer to developing clinical care that is individually oriented. It is however, clear that some issues like the absence seizure of legal and regulatory policies for the new system will arise (C ollins & Hamburg, 2013). There are signs that the authorities are committed to developing the most conducive policies to alter the effective and ethical application of the genomic sequencer. The use of the genomics sequencing technology has the potential to attract ethical issues like insurance companies being acquainted with genomic information about their clients, which could father the development of exempted services that might be discriminating (Collins & Hamburg, 2013). Access to genomic information by physicians may also lead to substandard applications of the system. It is required that the development of close genomic information must be attained through thorough processes that may require recurrent experimentation (Collins & Hamburg, 2013). The FDA is collaborating with the National Institute for Standards and Technology to design the required interpretive material for physicians.